Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-Pyridoxyl-Glycine‑5‑Monophosphate is a synthetic small molecule derivative of pyridoxamine (a form of vitamin B6), in which glycine is conjugated to the pyridoxal ring and a phosphate group is attached at the 5-position. It acts as an experimental inhibitor of ornithine decarboxylase, an enzyme involved in polyamine biosynthesis. The compound has been studied primarily as a biochemical tool and not as an approved pharmaceutical agent. There are no known clinical indications or marketed formulations for this molecule[1][2][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on n-pyridoxyl-glycine-5-monophosphate.